MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Galapagos NV

< Previous 1 2 3 Next >
News headline image
Galapagos Receives Transparency Notification from Bank of America
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Receives Transparency Notifications from Bank of America
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Creates New Subscription Right Plan
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Appoints Tania Philipp as Chief Human Resources Officer
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Receives Transparency Notifications from Bank of America
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Welcomes Dr. Paulo Fontoura to its Board of Directors
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Receives Transparency Notification from Bank of America
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Receives Transparency Notifications from Bank of America
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Receives Transparency Notifications from Bank of America
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos to Present New Data from Cell Therapy Program at ASH 2025
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Announces Appointment of Fred Blakeslee as General Counsel
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Creates New Subscription Right Plan
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Appoints Aaron Cox as Chief Financial Officer
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101
From Galapagos NV
Via GlobeNewswire
News headline image
Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes
From Galapagos NV
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story